Preop MRI for breast cancer: Intuition no substitute for data

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

For clinicians, MRI may offer a more in-depth view than mammography for planning surgery and screening for contralateral breast cancers, but does use of MRI actually benefit patients?

SAN FRANCISCO—For clinicians, MRI may offer a more in-depth view than mammography for planning surgery and screening for contralateral breast cancers, but does use of MRI actually benefit patients?

"It seems intuitively obvious that MRI does help us, and in our heart of hearts, we think it probably does, but there is no proof," Kimberly Van Zee, MD, a surgical oncologist at Memorial Sloan-Kettering Cancer Center, said at a "current controversies" session of the 2007 ASCO breast cancer symposium.

"Over the last 10 years, the technology has developed tremendously," she said. "We're seeing remarkable, beautiful detail. It's almost seductive. We think 'how can it be bad to know all this good information?' It's intuitively obvious, but there are no data."

Dr. Van Zee also pointed to a possible increase in mastectomy rates with the use of breast MRI, adding her voice to those of other skeptics who say MRI may raise the mastectomy rate unnecessarily.

Retrospective studies

There are retrospective studies that hint at benefit of preoperative MRI for patients diagnosed with breast cancer, including Fischer et al (Eur Radiol 14:1725-1731, 2004).

The Fischer study showed a significantly lower local recurrence rate at 40 months post-treatment in women who underwent preoperative MRI, compared with those who did not (1.2% vs 6.8%). Contralateral breast cancer rates during follow-up were also significantly lower (1.7% vs 4%).

However, it remains unclear whether the lower local recurrence rate in this study was actually a result of the preoperative MRI staging, since, Dr. Van Zee said, the cancers of the study participants undergoing MRI were of a lower stage than those of the women who did not have an MRI.

In the United Kingdom, researchers have raised similar concerns about the use of MRI, not only preoperatively but for surveillance.

"I think the issue of using MRI as a surveillance tool in follow-up after breast cancer surgery is a difficult one. There is no evidence to date of benefit," Professor Fiona J. Gilbert, the Roland Sutton Chair of Radiology at the University of Aberdeen, told Oncology NEWS International.

Professor Gilbert and her colleagues await results of the COMICE study, which is examining the benefit of utilizing MRI as a staging procedure to reduce the re-operation rate following primary excision and the ipsilateral local recurrence rate.

The study is randomizing 1,850 women with biopsy-proven primary breast cancer scheduled for wide local excision to MRI or no further investigation beyond routine techniques.

For those raising questions over the benefit of MRI, the plea is simple: "Everyone needs to participate in national trials," Dr. Van Zee said. "We need to prove that it's helpful or that it isn't helpful so that we don't mislead ourselves into thinking that it really is helping people."

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.